Respiratory diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma, the most common chronic disease. Each year, tens of millions of people develop and can die from respiratory infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for those affected. Current treatment options for lung diseases are neither always effective, nor often condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases are not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung diseases, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, fellows, and students with new perspectives and concepts. The editor hopes this book will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.

Lung diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma. Each year, tens of millions of people develop and can die from lung infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for some patients. Current treatment options for lung disease are neither always effective, nor condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung disease, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, and students with new perspectives and concepts. The editors hope these books will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.

Respiratory diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma, the most common chronic disease. Each year, tens of millions of people develop and can die from from respiratory infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for those affected. Current treatment options for lung disease are neither effective, nor condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung disease, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, and students with new perspectives and concepts. The editors hope these books will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.

Lung diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma. Each year, tens of millions of people develop and can die from lung infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for some patients. Current treatment options for lung disease are neither always effective, nor condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung disease, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, and students with new perspectives and concepts. The editors hope these books will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.

This book provides an overview of the latest experimental work on sex-based differences in lung function and inflammation. Readers will learn how these differences relate to individual predispositions for the development of lung disease in men and women, and in different stages of their reproductive lives. Further, the book focuses on diseases that predominantly affect women or men, with an emphasis on the physiological mechanisms underlying their pathobiology. In turn, these findings are complemented by chapters on recent studies, which investigate how circulating sex hormone levels impact the lung’s innate immune response to environmental agents and air pollution. The pathogeneses of asthma and viral respiratory infection are also major focus areas. As an outlook, the book also discusses current and future research directions aimed at developing sex-specific therapies for lung disease. To examine these anatomical and physiological differences in the male and female respiratory systems, the authors employ a broad range of methods from molecular and clinical biology. Accordingly, the book will be a fascinating read for physiologists and clinicians alike.

Pulmonary diseases are the major cause of human morbidity, taxing the health care system due to disease prevalence, chronicity, and social and fiscal costs. This book concentrates on the inflammatory and immunogenic settings of pulmonary disorders and related medical areas. Excessive inflammation causes lung injury and forms a conducive background for pathogenic infections, particularly in immuno-compromised hosts. Bacterial immuno-evasive strategies develop, leading to self-perpetuating pathologies. Inflammation also is an essential component of non-communicable lung diseases, including asthma and respiratory allergies, and smoking-related or granulomatous diseases. The chapters combine a strong grounding in basic science with extensive clinical knowledge and experience. Advances in diagnostics, as well as preventive and therapeutic aspects also are tackled. The book provides useful information to clinicians, researchers, health care and other medical professionals.

"This Ebook is edited by Sandra Hodge, a recognized expert in the field of macrophage dysfunction in chronic lung disease. The book consists of 8 chapters which provide a full coverage of macrophage function in both healthy and chronically diseased lungs, "

Rhinovirus Infections: Rethinking the Impact on Human Health and Disease provides a timely review of the impact of rhinovirus infections on human health. It identifies disease mechanisms relating to the virus, human host and environmental factors. This viewpoint allows us to look forward to the development of treatments for a virus for which treatment options are currently non-existent. By providing detailed insights into this virus, its host and the environmental factors that play into rhinovirus induced diseases, this book explains disease mechanisms and summarizes existing and developing therapeutic approaches for better research, diagnosis and potential treatments. Provides insight into viral diversity and identification of virulence factors, showing how the subtype of rhinovirus affects susceptibility to diseases Explores host and environmental factors, explaining how age, health status, genotype, lifestyle and environment influence the outcome of a rhinovirus infection Covers vaccines and treatments, discussing the health burden associated with rhinovirus infections and the driving development of an increasing array of treatment approaches

Mitochondria, often referred to as the “powerhouses” of the cell, generate adenosine triphosphate (ATP) by oxidative phosphorylation or OXPHOS, and maintain cellular homeostasis. In addition to generating ATP, mitochondria are involved in regulation of cell cycle, proliferation, free radical production, innate immune responses and apoptosis. Mitochondrial Function in Lung Health and Disease fills the current gap in the literature and outlines the growing clinical relevance of mitochondrial dysfunction. Currently, there is no overview on the role of mitochondria in pulmonary diseases and this volume focuses on the mitochondrial metabolism, redox signaling, and mechanisms of mitochondrial pathways in lung injury, inflammation, repair and remodeling. Furthermore, in addition to their well-recognized role in cellular energy production and apoptosis, mitochondria appear to play a role in many respiratory diseases and lung cancer. Chapters are written by top notch researchers and clinicians and outline the evidence for mitochondrial biogenesis in inhalational lung injury, COPD and asthma.

The Pulmonary Endothelium is a uniquely comprehensive compendium of our current knowledge of the pulmonary endothelium and is the first book dedicated specifically to the subject, offering insights into current and future approaches to management. The text provides the clinician with the most up-to-date information on one of the core physiological processes in airway disease and is an ideal point of reference for both postgraduates and professionals – specialist physicians in pulmonology and allergy and workers in biomedical and pharmaceutical research.